SCHEMBL5413552

SCHEMBL5413552

COc1ccc(CSc2cnc(O)nc2O)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 2/20 0.48
TP53 P04637 1/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
MEN1 O00255 1/20 0.45
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45
KMT2A Q03164 1/20 0.45
RELA Q04206 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
FFAR1 O14842 1/20 0.44
MAOB P27338 2/20 0.43
MAOA P21397 1/20 0.43
APP P05067 1/20 0.43
ALDH1A1 P00352 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
IDO1 P14902 2/20 0.42
CTSB P07858 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5402428 0.85 DAO (0.45) DAOTP53NPC1RAB9AMEN1
SCHEMBL27577280 0.74 DAO (0.54) DAOTP53NPC1RAB9AMEN1
SCHEMBL5408788 0.74 TP53 (0.48) DAOTP53NPC1RAB9AMEN1
SCHEMBL10687383 0.72 APP (0.58) DAOTP53NPC1RAB9AMEN1
SCHEMBL26601680 0.71 TP53 (0.45) DAOTP53NPC1RAB9AMEN1
SCHEMBL31294325 0.71 L3MBTL1 (0.45) DAOTP53NPC1RAB9AMEN1
SCHEMBL30080093 0.70 PSEN1 (0.48) NPC1RAB9AMEN1NFKB1NFKB2
SCHEMBL5425880 0.70 MAPT (0.43) DAOTP53NPC1RAB9AMEN1
SCHEMBL97659 0.70 NPC1 (0.54) DAOTP53NPC1RAB9AMEN1
SCHEMBL23663276 0.70 ABCB1 (0.49) DAONPC1RAB9AMAOBCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7166599-B2 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-01-23 US disclosed
US-20050090486-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-04-28 US disclosed
EP-1453516-A2 NOVEL TRI-SUBSTITUTED PYRIMIDINES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2004-09-08 EP disclosed
US-20030134838-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-07-17 US disclosed
WO-2003032994-A2 NOVEL TRI-SUBSTITUTED PYRIMIDINES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134838-A1 Trisubstituted pyrimidines APP, PSEN1, BACE1 DAO 2165/4885TP53 1261/4885NPC1 679/4885
US-20050090486-A1 Trisubstituted pyrimidines APP, BACE1, PSEN1 DAO 2033/4885TP53 580/4885NPC1 1758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.